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Electrochemotherapy (ECT) enhances responsiveness to cytotoxic drugs in numerous cell lines in 30 
vitro. Clinically ECT is widely applied for skin tumor ablation and has shown efficacy in treating non-31 
resectable colorectal liver metastases. There is limited experience of ECT for ocular tumor therapy. 32 
We investigated the cytotoxic effect of bleomycin and cisplatin in combination with electroporation 33 
on chemoresistant human uveal melanoma (UM) cell lines in vitro. Four UM cell lines (Mel 270, 92-1, 34 
OMM-1, OMM-2.5) were treated with electroporation (pulse amplitude 300-1000 V/cm, 8-80 pulses, 35 
100µs, 5 Hz) and increasing concentrations of bleomycin and cisplatin (0-7.5µg/ml). Cell survival was 36 
analyzed byMTT viability assay after 36 hours. UM cell lines were resistant to both bleomycin and 37 
cisplatin. In combination with electroporation, the effects of bleomycin and cisplatin were 38 
increased8–70 fold and 3–15 fold,respectively, in all UM cell lines. At the lowest concentration of 39 
bleomycin tested (1µg/ml),viability was maximally reduced in all UM cell lines by ≥69% with 40 
electroporation conditions of 750 Volts/cm and 20 pulses. All UM cell lines were more resistant to 41 
cisplatin; however, electroporation of 1000Volts/cm and 8 pulses resulted in similar reductions in cell 42 
viability of 92-1, Mel270 with2.5µg/ml cisplatin, OMM2-5 cells with 5µg/ml cisplatin and OMM1 cells 43 
with 1µg/ml cisplatin.In vitroECT with bleomycin or cisplatin is more effective than the highest 44 
concentration of the antineoplastic drug or electroporation alone, opening new perspectives in 45 












Disseminated uveal melanoma (UM) is clinically resistant to many chemotherapy drugs, and indeed 54 
the current standard of care, dacarbazine, is effective in <8% of individuals with metastaticUM [1,2]. 55 
The mechanisms for the relative innate chemoresistance of UM cells are unclear. Those 56 
chemoresistance mechanisms previously described in cancer include: decreased drug accumulation; 57 
enhanced anti-apoptotic mechanisms; and increased/altered DNA repair pathways. Electroporation, 58 
which is based on the local application of short and intense electric pulses that transiently 59 
permeabilise cells, has been used to enhance drug entry into otherwise chemoresistant cancer cells 60 
and resulted in their death [3-10]. This process of electrochemotherapy (ECT) is also used currently in 61 
clinical practice to treat cutaneous and subcutaneous tumor nodules in patients with progressive 62 
disease of different malignancies,e.g.soft tissue sarcomas and carcinomas,cutaneous melanoma 63 
[11,12], as well as colorectal liver metastases, located in the vicinity of major hepatic vessels, not 64 
amenable to surgery or radiofrequency ablation [13]. The treatment can result in complete 65 
responses of the tumors with very limited side effects [11]with drug doses that by themselves have 66 
minimal or no antitumor activity.   67 
Amongst the several clinically-approved drugs that have been tested in pre-clinical studies of ECT, 68 
bleomycin and cisplatin have been shown to be highly effective [4,8]; exposure of cells to electric 69 
pulses increases the cytotoxicity of bleomycin and cisplatin given either intravenously or intra-70 
tumorally [14-16]. Previous studies examining the efficacy of cisplatin in UM cells isolated from 71 
primary tumors demonstrated no effect of the drug to reduce cell number in nine cultures tested 72 
[17]. 73 
In order to determine whether chemoresistance in UM is due to an inability to accumulate drug 74 
inside the cancer cell, this study evaluated the cytotoxic effect of cisplatin or bleomycin after 75 
electroporation of four UM cell lines; Mel 270, 92-1, OMM-1 and OMM-2.5. The initial 76 
electroporation conditions were selected according to the ESOPE protocol [12]. The aim of the study  77 




was to examine the effect of ECT on cell viability after reduction of the voltage/pulses combined with 78 
different concentrations of the drug. These parameters would support the hypothesis that ECT could 79 
be applied on the eye with minor side effects. 80 
 81 




Materials and Methods 82 
Cell lines and culture 83 
The human UM cell lines 92-1and Mel270, derived from primary tumor and the OMM-1 as well as 84 
OMM-2.5, derived from subcutaneous and liver metastasis respectively, were kindly provided by 85 
Prof. Dr. Martine Jager, Leiden University Medical Centre (LUMC), The Netherlands. All cell lines have 86 
been STR profiled and mycoplasma tested. They were grown in Roswell Park Memorial Institute 87 
(RPMI) 1640 medium containing 10% fetal bovine serum, 1% L-Glutamine (all from Invitrogen, GIBCO, 88 
USA) and 2% Penicillin Streptomycin (Thermo Fisher Scientific, USA). All cell lines were maintained as 89 
monolayers in 175 cm² tissue culture flasks (Thermo Fisher Scientific, USA) at 37 °C in a humidified 90 
atmosphere containing 5% CO2.  91 
In vitro Electrochemotherapy (ECT) 92 
When cells reached 70% confluence they were harvested with 0.05% trypsin, counted and 1x106 cells 93 
were re-suspended in 400µl of RPMI,with or without bleomycin or cisplatin, in a 4mmgap 94 
electroporation cuvette with parallel aluminum plate electrodes (Geneflow, UK). A range of 95 
electroporation conditions were applied to the cell suspensions usingthe voltage pulse generator 96 
(CliniporatorTM) designed by Igea S.p.A. (Capri, Modena, Italy). Details of all experimental conditions 97 
are given below.  98 
All cells were treated with 0, 1 µg/ml, 2.5 µg/ml, 5 µg/ml and 7.5 µg/ml bleomycin or cisplatin 99 
combined with all following electroporation settings: 100 
(A) No electroporation; 101 
(B) 80 square wave electric pulses of 300 Volts/cm pulse strength, 100 µs pulse duration, 5 Hz 102 
repetition frequency; 103 
(C) 40 square wave electric pulses of 300 Volts/cm pulse strength, 100 µs pulse duration, 5 Hz 104 
repetition frequency; 105 




(D) 40 square wave electric pulses of 500 Volts/cm pulse strength, 100 µs pulse duration, 5 Hz 106 
repetition frequency; 107 
(E) 20 square wave electric pulses of 500 Volts/cm pulse strength, 100 µs pulse duration, 5 Hz 108 
repetition frequency; 109 
(F) 20 square wave electric pulses of 750 Volts/cm pulse strength, 100 µs pulse duration, 5 Hz 110 
repetition frequency; 111 
(G) 8 square wave electric pulses of 750 Volts/cm pulse strength, 100 µs pulse duration, 5 Hz 112 
repetition frequency; 113 
(H) 8 square wave electric pulses of 1000 Volts/cm pulse strength, 100 µs pulse duration, 5 Hz 114 
repetition frequency. 115 
Following treatment, 2x104 cells were pipetted into 6 wells of a 96-well plate for each treatment 116 
condition and RPMI was added up to a maximum volume of 100µl. The plates were then incubated 117 
for 36 hours.  118 
The protocol was conducted for all fourUM cell lines. Each experiment was performed in triplicate on 119 
different dates, giving a total of 18 biological replicates for each ECT setting.  120 
MTT viability assay 121 
RPMI-1640 medium was aspirated from each wellafter 36 hours and 3-(4,5-dimethylthiazol-2-yl)-2,5-122 
diphenyltetrazolium bromide (MTT, Sigma-Aldrich, USA) stock solution (5 mg/ml) was added to each 123 
well, equal to one-tenth the original culture volume following the protocol provided by Sigma-Aldrich 124 
(90 µl media and 10 µl MTT). All plates were then incubated at 37 °C for 4 hours. Following this, the 125 
solution was removed and the formazan formed in the cells was dissolved using 100 µl of a 1:1 126 
solution of dimethyl sulfoxide (DMSO, Sigma-Aldrich, USA) and 2-propanol (isopropanol, Sigma-127 
Aldrich, USA). Absorbance of converted dye was measured with a SPECTRAFLUOR (Tecan, Austria) 128 
spectrometer at a wavelength of 570 nm.  129 
 130 





Each of the fourUM cell lines were exposed to eight different electrical fields. The duration of 100µs 132 
and the pulse frequency of 5Hz remained stable whereas the amplitude and the number of pulses 133 
varied.Electroporation alone, reduced cell viability in all cell lines at amplitudes of 500 Volts/cmor 134 
higher and this effect was augmented with increasing number of pulses. The greatest reduction in 135 
cell viability was noted at 1000 Volts/cm for 8 pulses across all four cell lines ranging from a 29.5% 136 
reduction in the most sensitive 92.1 cell line to a 25.0% reduction in the least sensitive OMM-2.5 cell 137 
line (Figure 1). 138 
Bleomycin alone had no effect on cell viability in the OMM-1 and OMM-2.5 cell lines and reduced cell 139 
viability in the 92.1 and Mel270 cell lines by <10% at the maximum concentration tested (7.5µg/ml; 140 
(Figure 2A).When electroporation conditions ≥750 Volts/cm were administered to the UM cells, 141 
however, bleomycin cytotoxicity was maximally increased by 8-fold in the 92.1 cell line, 25-fold in the 142 
Mel270 cell line and by more than 70-fold in the OMM-1 and OMM-2.5 cell lines (Figure 3). In order 143 
to minimize systemic toxicity of bleomycin, we were interested in the electroporation conditions that 144 
in combination with the lowest dose of bleomycin tested (1µg/ml) had the maximal effect to reduce 145 
cell viability. In the 92.1 and Mel270 cell lines this was achieved at 750 Volts/cm for 20 pulses, 146 
reducing cell viability by 74% and 69%, respectively (Figure 3A and 3B). In the OMM-1 and OMM-2.5 147 
cell lines there was little difference between the effectiveness of 1µg/ml bleomycin when combined 148 
with electroporation conditions of either 750 Volts/cm for 20 pulses or 1000 Volts/cm for 8 pulses, 149 
with a reduction in cell viability of between 76% and 89% (Figure 3C and 3D).  150 
Similar to bleomycin, cisplatin alone had little effect on cell viability at the concentrations tested 151 
(Figure 2B), with a maximum 15% reduction in viability of the 92.1 cell line at 7.5µg/ml cisplatin. 152 
When electroporation conditions ≥500 Volts/cm were administered to the UM cells, however, 153 
cisplatin cytotoxicity was maximally increased by 3, 6, 10 and 15-fold in the 92.1, Mel270, OMM-1 154 
and OMM-2.5 UM cell lines respectively (Figure 4). In combination with electroporation the most 155 




sensitive UM cell line was OMM-1, which showed an 80% reduction in cell viability with 1000 156 
Volts/cm for 8 pulses and 1µg/ml cisplatin (Figure 4C). In the 92.1, Mel270 and OMM-2.5 cell lines, 157 
higher concentrations of cisplatin in combination with electroporation conditions of 1000 Volts/cm 158 
for 8 pulses were necessary to achieve similar reductions in viability as noted for the OMM-1 cells. 159 
For example, 1000 Volts/cm for 8 pulses with 2.5µg/ml cisplatin was necessary to reduce viability of 160 
the 92.1 and Mel270 cell lines by 77% and 70% respectively (Figure 4A and 4B); whilst 1000 Volts/cm 161 
for 8 pulses with 5.0µg/ml cisplatin was necessary to reduce viability of the OMM-2.5 cell line by 75% 162 
(Figure 4D). 163 
164 




Discussion  165 
In this novel study we investigated the efficiency of electroporation with bleomycin and cisplatin in 166 
fourhuman UM cell lines that demonstrate resistance to these chemotherapeutic drugs at their 167 
commonly achieved peak plasma concentrations of 0.5 – 5.0µg/ml and 0.5 – 2.0µg/ml, respectively. 168 
We show for the first time that electroporation sensitizes UM cells to doses of either drug within 169 
these ranges.  170 
Bleomycin is an anti-tumor antibiotic that causes single and double strand DNA breaks in tumor cells 171 
resulting in cell death. It is used to treat a range of malignancies, including head and neck cancer, 172 
testicular carcinomas and lymphomas [18-22]. In UM it has been used in the metastatic setting as 173 
part of a multicentre study of bleomycin, vincristine, lomustine and dacarbazine (BOLD) in 174 
combination with recombinant interferon alpha-2b, although only a modest effect of this regimen 175 
against UM at hepatic sites was reported [23]. Cisplatin is another commonly used anti-cancer agent 176 
that causes DNA crosslinks resulting in DNA damage, and subsequently inducing apoptosis in cancer 177 
cells.It is commonly used in the treatment of lung-, ovarian-, and head-and-neck carcinomas, but has 178 
been shown to have little effect in combination chemotherapy for metastatic UM [24].  179 
Bleomycin is a large non-permeant drug, a characteristic that contributes to the resistance of many 180 
cell types to this agent [25]. Studies on the Chinese hamster lung cell line (DC-3F) have shown that if 181 
bleomycin can enter the cell, <500 molecules of the drug are needed to cause cell death [25,26]. 182 
Althoughresistance to cisplatin is considered to be multifactorial, evidence suggests that plasma 183 
membrane transporters resulting in the extrusion of cisplatin play a major role in the resistance 184 
mechanism(s)[27]. 185 
In this study we have shown that by applying an electrical field to UM cells above a threshold 186 
amplitude of 500 Volts/cm, sensitivity to bleomycin and cisplatin are greatly increased, and that this 187 
is further enhanced by an increased number of pulses as has previously been reported [28.29]. 188 
Electroporation creates transient permeable pores in the cell membrane thus enhancing drug entry 189 




and accumulation in the cell [30,31], and indeed ECT has been shown to be effective in a variety of 190 
other tumor cell types in vitro[3-10]. Furthermore, ECT for skin metastases from tumors of non-191 
cutaneous origin as well as for skin melanoma is currently part of the NICE interventional procedure 192 
guidance for these lesions [32].  193 
Small differences in the sensitivity of the cell lines to ECT with both bleomycin and cisplatin were also 194 
noted. In particular, the OMM-1 cell line was more sensitive to ECT with cisplatin than the 92.1, 195 
Mel270 and OMM-2.5 cell lines. OMM-1 cells are derived from a subcutaneous metastatic UM; whilst 196 
92.1 and Mel270 cells, are derived from primary tumors, and OMM-2.5 is from a hepatic UM 197 
metastasis. Previous studies have reported thatcell size, shape, membrane structure, composition 198 
and transmembrane potential can affect electroporation [33,34]. In the current study no differences 199 
were observed in the response of the four UM cell lines to electroporation despite striking 200 
differences in the size and shape of these cells. We did not examine, however, other membrane 201 
features, but this will be pursued in primary and metastatic UM cell cultures in the near future. 202 
Various preclinical models are available for the study of primary and metastatic UM, and would lend 203 
themselves to the examination of new and older chemotherapeutic agents in combination with ECT 204 
[35].  205 
In summary, electroporation provides a more targeted pathway into UM cells for bleomycin and 206 
cisplatin. The application of this treatment could lead to the shrinkage of large, non-treatable UM in 207 
order to enable a further surgical intervention and avoid enucleation as primary treatment. 208 
Furthermore the application of ECT could allow a lower drug doses and a reduction of systemic side 209 
effects in the treatment of large non-resectable UM hepatic metastases, as has been demonstrated 210 
in colorectal liver metastases located close to major hepatic vessels, not amenable to other 211 
treatments [13]. The combination of various chemotherapy agents and ECT thus requires further 212 
investigation in vitro and in vivo to investigate the challenges of a clinical application of the protocol 213 
in disseminated UM.  214 
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Figure legends 301 
 Figure 1 – Effects of electroporation on cell viability 36 hours following exposure. Data are the mean 302 
± SEM of 6 individual experiments for the 92.1 (black bars), Mel270 (Dark grey bars), OMM-1 (white 303 
bars) and the OMM-2.5 (hashed bars) cell lines. 304 
Figure 2 – Effects of (A) bleomycin and (B) cisplatin on viability of the 92.1 (solid black line), Mel270 305 
(dotted black line), OMM-1 (solid grey line) and OMM-2.5 (dashed black line) UM cell lines 36 hours 306 
after exposure to the drugs. Data are the mean ± SEM of 3 separate experiments. 307 
Figure 3 – Cytotoxic effects of increasing doses of bleomycin on the viability of (A) 92.1, (B) Mel270, 308 
(C) OMM-1 and (D) OMM-2.5 UM cell lines following electroporation. Data are the mean of 18 309 
replicates across three separate experiments for the effect of electroporation alone (black bars), 310 
1µg/ml (dotted bars), 2.5µg/ml (grey bars), 5µg/ml (striped bars) and 7.5µg/ml (white bars) 311 
bleomycin to reduce cell viability. 312 
Figure 4 – Cytotoxic effects of increasing doses of cisplatin on the viability of (A) 92.1, (B) Mel270, (C) 313 
OMM-1 and (D) OMM-2.5 UM cell lines following electroporation. Data are the mean of 18 replicates 314 
across three separate experiments for the effect of electroporation alone (black bars), 1µg/ml 315 
(dotted bars), 2.5µg/ml (grey bars), 5µg/ml (striped bars) and 7.5µg/ml (white bars) cisplatin to 316 
reduce cell viability. 317 
